|17.88||+0.4400||+2.52%||Vol 839.35K||1Y Perf 1.22%|
|May 13th, 2022 16:00 DELAYED|
|- -||0.37 2.07%|
|Target Price||28.40||Analyst Rating||Hold 2.60|
|Potential %||58.84||Finscreener Ranking||★★+ 47.78|
|Insiders Trans % 3/6/12 mo.||-/-/-||Value Ranking||★+ 43.33|
|Insiders Value % 3/6/12 mo.||-/-/-||Growth Ranking||★★+ 49.47|
|Insiders Shares Cnt. % 3/6/12 mo.||-/-/-||Income Ranking||— -|
|Price Range Ratio 52W %||58.36||Earnings Rating||Strong Buy|
|Market Cap||531.27M||Earnings Date||6th May 2022|
Today's Price Range
5 Year PE Ratio Range
|Moving Averages:||Strong Buy|
|Mngmt Effectiveness||Value||Industry||S&P 500||US Markets|
ROE (5Y Avg)
ROE last 12 Months
ROA (5Y Avg)
ROA last 12 Months
ROC (5Y Avg)
ROC last 12 Months
Return on invested Capital Q
Return on invested Capital Y
|Earnings History||Estimate||Reported||Surprise %|
|Earnings Per End||Estimate||Revision %||Trend|
|Next Report Date||-|
|Estimated EPS Next Report||-0.89|
|EPS Growth Next 5 Years %||-|
|Avg. Weekly Volume||1.39M|
|Avg. Monthly Volume||1.40M|
|Avg. Quarterly Volume||1.03M|
Intercept Pharmaceuticals Inc. (NASDAQ: ICPT) stock closed at 17.88 per share at the end of the most recent trading day (a 2.52% change compared to the prior day closing price) with a volume of 839.35K shares and market capitalization of 531.27M. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 498 people. Intercept Pharmaceuticals Inc. CEO is Jerome B. Durso.
The one-year performance of Intercept Pharmaceuticals Inc. stock is 1.22%, while year-to-date (YTD) performance is 9.76%. ICPT stock has a five-year performance of -84.74%. Its 52-week range is between 11.6 and 22.36, which gives ICPT stock a 52-week price range ratio of 58.36%
Intercept Pharmaceuticals Inc. currently has a PE ratio of -6.80, a price-to-book (PB) ratio of 52.34, a price-to-sale (PS) ratio of 1.90, a price to cashflow ratio of -, a PEG ratio of 2.32, a ROA of -17.13%, a ROC of -49.87% and a ROE of 53.89%. The company’s profit margin is -18.37%, its EBITDA margin is -10.10%, and its revenue ttm is $281.81 Million , which makes it $9.48 revenue per share.
Of the last four earnings reports from Intercept Pharmaceuticals Inc., there were 4 positive earnings surprise and 0 negative earnings surprise. The company has EPS estimate of $-0.89 for the next earnings report. Intercept Pharmaceuticals Inc.’s next earnings report date is -.
The consensus rating of Wall Street analysts for Intercept Pharmaceuticals Inc. is Hold (2.6), with a target price of $28.4, which is +58.84% compared to the current price. The earnings rating for Intercept Pharmaceuticals Inc. stock is Strong Buy (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).
Intercept Pharmaceuticals Inc. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.
Intercept Pharmaceuticals Inc. has a Buy technical analysis rating based on Technical Indicators (ADX : 27.45, ATR14 : 1.28, CCI20 : 63.66, Chaikin Money Flow : 0.31, MACD : 0.41, Money Flow Index : 80.38, ROC : 14.03, RSI : 54.21, STOCH (14,3) : 58.35, STOCH RSI : 0.21, UO : 51.98, Williams %R : -41.65), Simple Moving Averages and Exponential Moving Averages.
Aggregated Insider Trades of Intercept Pharmaceuticals Inc. in the last 12-months were:
Mon, 09 May 2022 18:05 GMT Analysts Offer Insights on Healthcare Companies: Intercept Pharma (ICPT) and Amicus (FOLD)- TipRanks. All rights reserved.
Sat, 07 May 2022 03:32 GMT Intercept Pharma (ICPT) Receives a Buy from Robert W. Baird- TipRanks. All rights reserved.
Thu, 03 Mar 2022 17:25 GMT Intercept Pharma (ICPT) Gets a Buy Rating from B.Riley Financial- TipRanks. All rights reserved.
Thu, 03 Mar 2022 12:36 GMT Analysts Conflicted on These Healthcare Names: Mesoblast (MESO), Intercept Pharma (ICPT) and Chimerix (CMRX)- TipRanks. All rights reserved.
Wed, 02 Mar 2022 19:10 GMT Intercept Pharma (ICPT) Receives a Hold from JMP Securities- TipRanks. All rights reserved.
Fri, 07 Jan 2022 01:50 GMT Intercept Pharma (ICPT) Gets a Hold Rating from RBC Capital- TipRanks. All rights reserved.
Copyright © 2016-2022 Finscreener.org. All Rights Reserved.
Disclaimer: Before deciding to trade you should carefully consider your investment objectives, level of experience and your risk appetite. Forex and Tradegate data is a real-time with a 30 second refresh. Prices may not be accurate and may differ from the actual market price. Prices on the website are indicative and solely for informational purposes, not for trading purposes or advice. Please be aware of the risks associated with trading the on financial markets, it is one of the riskiest investment forms. Past performance does not guarantee future profits. We take no responsibility for any losses that may arise as a result of the data contained on this website. The content and the website are provided "as is", without any warranties. In no event will Finscreener.org, its employees, owners, directors, affiliates, partners, data provider, third party or anyone else liable to anyone else for any decision made regarding information on this website.
eToro USA LLC does not offer CFDs and makes no representation and assumes no liability as to the accuracy or completeness of the content of this publication, which has been prepared by our partner utilizing publicly available non-entity specific information about eToro. Your capital is at risk.
This could take some time, please wait.